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Impaired T-cell migration to the CNS
under fingolimod and dimethyl fumarate
ABSTRACT
Objective: To evaluate the long-term effects of treatments used in MS on the T-cell trafficking
profile.
Methods: We enrolled 83 patients with MS under fingolimod (FTY), natalizumab (NTZ), dimethyl
fumarate (DMF), or other disease-modifying treatments (DMTs). Blood was drawn before treat-
ment onset and up to 36–48 months. The ex vivo expression of CNS-related integrins (a4b1
and aL subunit of LFA-1) and the gut-related integrin (a4b7) was assessed using flow cytometry
on CD41 and CD81 T cells. The adhesion profiles of CD31 T cells to specific integrin ligands
(vascular cell adhesion molecule-1 [VCAM-1], intercellular adhesion molecule-1 [ICAM-1], and
mucosal vascular addressin cell adhesionmolecule-1 [MAdCAM-1]) were measured in vitro before
and after 12 and 36–48 months.
Results: NTZ decreased the frequency of a4b11 and a4b71 integrin expressing T cells and the
binding of these cells to VCAM-1 and MAdCAM-1, respectively. After 12 months, DMF induced
a decreased frequency of aLhighCD41 T cells combined with reduced binding to ICAM-1. By
contrast, with FTY, there was a doubling of the frequency of a4b11 and aLhigh, but a decreased
frequency of a4b71 T cells. Strikingly, the binding of a4b11, a4b71, and to a lesser extent of
aL
high T cells to VCAM-1, MAdCAM-1, and ICAM-1, respectively, was decreased at month 12
under FTY treatment. The presence of manganese partially restored the binding of these T cells to
VCAM-1 in vitro, suggesting that FTY interferes with integrin activation.
Conclusions: In addition to NTZ, DMF and FTY but not other tested DMTs may also decrease T-
cell–mediated immune surveillance of the CNS. Whether this mechanism may contribute to the
onset of CNS opportunistic infections remains to be shown. Neurol Neuroimmunol Neuroinflamm
2017;4:e401; doi: 10.1212/NXI.0000000000000401
GLOSSARY
ANOVA 5 analysis of variance; DMF 5 dimethyl fumarate; DMT 5 disease-modifying treatment; FOV 5 field of view; FTY 5
fingolimod; GA 5 glatiramer acetate; HC 5 healthy control; ICAM-1 5 intercellular adhesion molecule-1; IFN 5 interferon;
MACS 5 magnetic-activated cell sorting; MAdCAM-1 5 mucosal vascular addressin cell adhesion molecule-1; NTZ 5 na-
talizumab; PBS 5 phosphate-buffered saline; PBMC 5 peripheral blood mononuclear cell; PML 5 progressive multifocal
leukoencephalopathy; RRMS 5 relapsing-remitting MS; VCAM-1 5 vascular cell adhesion molecule-1.
MS is a debilitating disease resulting from combined genetic predisposition and environmental
factors. Several agents have been approved for relapsing-remitting MS (RRMS), with varying
efficacy and side-effect profiles. Fingolimod (FTY), dimethyl fumarate (DMF), and natalizumab
(NTZ) are disease-modifying treatments (DMTs) used in MS, acting on immunoinflammatory
components of the disease.1 Although occurring more rarely than with NTZ, cases of progressive
multifocal leukoencephalopathy (PML) have been reported in patients with MS treated with
FTY and DMF.Moreover, other opportunistic CNS infections have been reported with FTY.2–6
The occurrence of these CNS opportunistic infections raises the question whether these DMTs
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may act on the immune surveillance of the
CNS.7 One hypothesis is that viral reactivation
in the CNS may be related to a suboptimal
immune surveillance via a modulation of the
migratory profiles of T cells under FTY and
DMF, such as it is observed with NTZ.
In this 4-year observational study, we aimed
to better understand the long-term effects of
DMF and FTY on the maintenance of T-
cell–mediated CNS immune surveillance. We
compared those 2 drugs with NTZ, known to
block the function of a4b1 and a4b7
integrins involved in CNS and gut T-cell
homing, respectively, and to other DMTs
(interferon [IFN]-b, glatiramer acetate [GA],
teriflunomide), which have not been associated
with CNS infections. Specifically, we examined
the effect of these different DMTs on the
expression and function of integrins previously
shown to mediate T-cell homing to the CNS or
the gut by comparison with NTZ mechanism
of action.
METHODS Subjects. We enrolled 83 patients with RRMS
treated with (1) FTY (0.5 mg/d, n 5 38), (2) NTZ (300 mg iv
monthly, n 5 14), (3) DMF (2 3 240 mg/d, n 5 20), or (4)
“other DMTs” (IFN-b 1a [3 3 44 mg/wk sc or 30 mg/wk im],
n5 8, GA [20 mg/d sc]: n5 2, teriflunomide [14 mg/d]: n5 1)
and followed them up to 48 months into treatment (table). Four-
teen healthy controls (HCs) were also enrolled. The diagnosis of
MS was made using the revised McDonald criteria.8 All blood
samplings were performed at least 3 months after corticosteroid
therapy. Blood samples were drawn just before (T0) and at 6, 12,
24, and 36–48 months into MS treatment or until its interrup-
tion (table). For NTZ, blood draw was performed just before the
Table Clinical data of patients enrolled
Age at study
entry,a y F:M ratio
Disease
duration,a y
EDSS
scorea
Total no. of
relapses before
treatment onseta
Total no. of relapses
during the period of
the treatmenta
Previous
treatmentb
No. of patients
reaching time point
FTY cohort
(n 5 38)c
39/14 26:12 9/9 1.5/
0.5
3/4.5 0.0/0.0 16 IFN-b 1a T6: 38
3 IFN-b 1b T12: 38
6 GA T24: 36
3 NTZ T36–48: 29d
2 cladribine
(phase III trial)
8 without
NTZ cohort
(n 5 14)
37.5/12 13:1 5.5/7 2.75/2 3/4 0.0/1.0 5 IFN-b 1a T6: 6
3 IFN-b 1b T12: 14
4 GA T24: 12
1 mitoxantrone
1 FTY
DMF cohort
(n 5 20)
42.5/16.5 13:7 9/11 1.5/1 2/3 0.0/0.0 6 IFN-b 1a T6: 11
2 IFN-b 1b T12: 20
1 GA T24: 0
1 teriflunomide
10 without
Other DMT cohorte
(n 5 11)
37.5/13 9:2 1.5/11 1.5/1 2/2.5 0.0/0.0 2 IFN-b 1a T6: 10
1 GA T12: 9
8 without T24: 4
HC cohort (n 5 14) 29.9/9.1 5:9 NA NA NA NA NA NA
Abbreviations: DMF 5 dimethyl fumarate; DMT 5 disease-modifying treatment; EDSS 5 Expanded Disability Status Scale; FTY 5 fingolimod; GA 5
glatiramer acetate; HC 5 healthy control; IFN-b 5 interferon-beta; NA 5 not applicable; NTZ 5 natalizumab.
aNumbers represent the median/interquartile range.
bWashout period in between treatments in months (median/interquartile range): FTY cohort 5 0.0/1.3; NTZ cohort 5 0.3/1.7; DMF cohort 5 0.1/0.0; other
DMT cohort 5 13.8/11.0.
c Twenty-nine patients were tested for phenotypes and functional assays presented in figures 1–3; and 9 for functional assays presented in figure 4.
d Ten patients reaching T36 and 19, T48.
e Eight patients under IFN-b 1a; 2 under GA, and 1 under teriflunomide.
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next injection (e.g., blood sample at T6 was drawn just before the
seventh cure). Peripheral blood mononuclear cells (PBMCs) were
isolated and frozen as previously described within 4 hours after
blood draw.9
Standard protocol approvals, registrations, and patient
consents. Enrolled patients were part of an ongoing open study
aiming at characterizing the effects of disease-modifying thera-
pies. This study was accepted by our institution’s review board
(protocol 107/13), and all participants provided their written
informed consent.
Ex vivo surface staining for flow cytometry analyses. To
assess the ex vivo level of expression of different surface markers,
thawed PBMCs9,10 were stained at 4°C for 30 minutes with the
following antibodies: CD3-APC-Cy7, CD8-Pacific Blue (both
from Becton Dickinson, Franklin Lakes, NJ), CD4-ECD
(Beckman Coulter, Brea, CA), CD11a-FITC (aL), CD49d-
APC (a4 integrin, both from Becton Dickinson), b7 integrin
PE (eBioscience, San Diego, CA), and CD29-Alexa700 (b1 in-
tegrin; BioLegend, San Diego, CA).11 Dead cells were excluded
using the Aqua LIVE/DEAD stain kit (Invitrogen AG, Waltham,
MA). A blinded investigator acquired the data on an LSRII flow
cytometer (Becton Dickinson) and analyzed using FlowJo soft-
ware (version 8.8.6; Tree Star Inc., Ashland, OR). All samples
from a given study participant were analyzed on the same day;
each set of experiments included patients from 2 to 3 different
categories of DMTs and at least 1 HC so that potential sources of
variation and technical side effects were minimized. All experi-
ments were performed within a short period of time, using the
same lots of antibodies and the same cytometer settings. Ex vivo
analyses were performed on T cells expressing high levels of aL
integrin subunit (aLhigh) or T cells coexpressing either a4 and b1
integrin subunits (a4b11 T cells) or the a4 and b7 integrin
subunits (a4b71 T cells) (see figure e-1 at Neurology.org/nn for
detailed gating strategy).
CD31 T-cell adhesion to integrin ligand-coated slides.
For functional binding assays, CD31 T cells were sorted within
thawed PBMCs by magnetic-activated cell sorting (MACS)
using anti-CD3 MicroBeads with an autoMACS Pro Separator
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. The purity of sorted cells was
checked by flow cytometry using CD3-APC-Cy7 antibodies
and counterstaining with Aqua LIVE/DEAD. In vitro binding
assays were performed only if the purity of sorted populations
reached at least 90%. Binding profiles of isolated CD31 T cells
were assessed as described.12 Briefly, recombinant purified cell
adhesion molecules (human intercellular adhesion molecule-1
[ICAM-1]/Fc, vascular cell adhesion molecule-1 [VCAM-1]/
Fc, and mucosal vascular addressin cell adhesion molecule-1
[MAdCAM-1]/Fc or control Delta/Notch-like EGF-related
receptor/Fc [100 nM; from R&D Systems, Minneapolis, MN])
were bound to epoxy slides (Thermo Scientific, Waltham, MA),
precoated with protein A (BioVision, Milpitas, CA), and
blocked with 1.5% bovine serum albumin in phosphate-
buffered saline (PBS) (pH 7.4) for 30 minutes before use.
One hundred thousand CD31 T cells/field were then incubated
at room temperature for 30 minutes on a rotating platform. To
measure the maximal level of integrin-mediated adhesion,
CD31 T-cell integrin affinity maturation was induced by
incubation of T cells in the presence of 1 mM MnCl2 (Sigma
Aldrich, St. Louis, MO) for 30 minutes. After washing steps in
PBS, adhering T cells were fixed with 2.5% (vol/vol) glutaral-
dehyde in PBS for at least 2 hours on ice. All samples from
a given study participant were analyzed on the same day; each
set of experiments included patients from 2 to 3 different cat-
egories of DMTs and at least 1 HC so that potential sources of
variation and technical side effects were minimized. The
number of cells per field of view (FOV) was quantified in
a blinded fashion using a counting ocular with a classical optical
microscope (Zeiss AxioSkop 40 320, objective Carl Zeiss
1016-758, W-pi 310).
Statistical analysis. Statistical analysis was performed with
GraphPad Prism software, version 7.00. To take into account
the few missing value, a Kruskal-Wallis analysis of variance
(ANOVA) was run to test (1) differences in between the 3 groups
of treatments only at T0 (FTY vs NTZ vs DMF vs other DMTs)
and (2) the effect of each treatment all along the treatment
duration (FTY, NTZ, DMF, or the other DMTs, T0 vs T6 vs
T12 vs T24 vs T36–48). p Values obtained from these ANOVA
are mentioned in the text as pKW. If the effect of the treatment
reached significance, the differences between immune responses
measured at T0 with the various subsequent time points were
analyzed with the nonparametric paired Wilcoxon ranked test.
Unless mentioned otherwise in the figure legend, a Bonferroni
correction was performed to take into account the comparisons
performed at multiple time points (T0 vs T6, T0 vs T12, T0 vs
T24, and T0 vs T36–48). p , 0.05 was considered statistically
significant for adjusted p values.
RESULTS FTY and DMF treatments affect T-cell
homing to the CNS and the gut. Integrins involved in
T-cell homing to the CNS. We first assessed changes in
the ex vivo profile of T-cell homing phenotypes
characteristic for the CNS and the gut under the 4
groups of DMTs by determining the surface expres-
sion of integrins on CD41 and CD81 T cells using
flow cytometry. Those were (1) the CNS-addressing
integrin a4b1 and the integrin subunit a-chain of
LFA-1 (a4b11, aLhigh, figure 1)13–17 and (2) the gut-
addressing integrin: a4b7 (a4b71, figure 2).18,19
No differences in between the 5 groups of partic-
ipants (patients with MS and HCs) could be de-
tected before treatment onset, i.e., at T0 as tested by
Kruskal-Wallis tests.
In the group of other DMTs, none of the markers
studied were associated with fluctuations in integrin
expression on T cells during the entire treatment
duration (figures 1 and 2, data in blue). As expected,
our findings confirmed that, under NTZ, the fre-
quency of a4b11 integrin–expressing CD41 and
CD81 T cells, especially at T12 and T24 (figure 1,
data in red) was reduced,11,20,21 supporting the notion
that T-cell trafficking to the CNS is diminished. We
also observed, at T24, a 2.2- and a 1.5-fold decrease
in the frequency of expression of the aL subunit of
LFA-1 on CD41 and CD81 T cells, respectively,
however without reaching significance (CD4:
pKW 5 0.057; CD8: pKW 5 0.670).
The situation was completely different in the case
of FTY. As expected, there was a global reduction of
both, CD41 and CD81 T-cell counts in the periph-
eral blood (data not shown). However, there was
a highly significant increase in the frequency of
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circulating T cells expressing CNS-related integrins
(a4b11 or aL of LFA-1) at all time points tested.
The median frequency of a4b11-expressing CD41
and CD81 T cells, as measured at T6, T12, T24,
and T36–48, exceeded baseline median values by
65%–92% (pKW , 0.0001) and 81%–92% (pKW
, 0.0001), respectively (figure 1, data in black).
The enhanced frequency of aL-expressing CD41
and CD81 T cells was even more impressive, being
1.9–4.2-fold (pKW , 0.0001) and 2.1–2.7-fold
(pKW , 0.0001) increased, respectively.
On DMF, a reduction of 35% and 36% in the fre-
quency of CD41 T cells expressing a4b1 or aL,
respectively, was present at T12, while no effect was
noted within CD81 T cells (figure 1, data in green).
Integrins involved in T-cell homing to the gut. Of inter-
est, in the cohort of FTY-treated patients, the expres-
sion profile of a4b7 integrin–mediating T-cell
Figure 2 The gut-trafficking phenotype of T cells is downregulated by NTZ and FTY
The frequency of a4b71 T cells was assessed by flow cytometry in CD31CD41 (left panels) or CD31CD81 T cells (right panels). The color code, the number of
patients tested, the statistics, and the abbreviations are exactly the same as in figure 1 (see legend to figure 1).
Figure 1 The CNS-trafficking phenotype of T cells is affected by NTZ, FTY, and DMF
Frequencies ofa4b11 oraLhigh T cells were assessed by flow cytometry inCD31CD41 (left panels) or CD31CD81 T cells (right panels). Datawere obtained before
treatment initiation (T0) and after 6 (T6), 12 (T12), 24months (T24), and 36–48months (T36–48) of treatment. Data of FTY-treated patients withMS appear in
black in the graphs (n5 29), NTZ in red (n5 14), DMF in green (n5 20), patients under other DMTs in blue (n5 11), and HCs in gray (n5 14). Box and whiskers
plots show median, 25th and 75th percentiles, and range. The mean is represented as a dot in the box. The asterisks represent significant differences for the
effect of time for a given treatment: in black for FTY-treated patients; in red, NTZ-treated patients; and in green, DMF-treated patients. *p, 0.05; **p, 0.01;
***p , 0.001; ****p , 0.0001. DMF5 dimethyl fumarate; DMT 5 disease-modifying treatment; FTY 5 fingolimod; HC5 healthy control; NTZ 5 natalizumab;
Others 5 other DMTs.
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homing to the gut was completely different from that
observed for a4b1 integrin and the subunit aL
of LFA-1. Indeed, we found that the frequency
of a4b71-circulating CD41 and CD81 T cells
decreased at least by 65% and 42%, respectively. This
pattern was similar to what is observed for NTZ, which
targets both a4b1 and a4b7 integrin–expressing T
cells (figure 2). By contrast, there was no significant
change in the frequency of a4b71 integrin–expressing
circulating T cells on DMF or other DMTs.
T-cell adhesion profiles under DMTs used in MS. Cell
surface coexpression of integrin subunits does not suf-
fice to determine proper integrin function that requires
a functional heterodimer and additional activation by
integrin affinity maturation. Thus, in a next step, we
determined whether MS DMTs have an effect on
integrin-mediated binding to their respective endo-
thelial ligands. To this end, we performed in vitro
binding assays focusing on the ability of CD31 T cells
to bind to VCAM-1 and ICAM-1 involved in T-cell
homing to the CNS and MAdCAM-1 involved in
T-cell homing to the gut (figure 3).
First, we did not observe any significant difference
in the adhesion of circulating T cells to all adhesion
molecules tested in the cohort of other DMTs (figure
3, data in blue). Regarding NTZ, as expected, we
found that the number of CD31 T cells adhering
to VCAM-1 and MAdCAM-1 dropped significantly
from 65 to 22 and from 7 to 2 cells/FOV, respectively
(figure 3, data in red). In line with the ex vivo phe-
notype (figures 1 and 2), no change in the binding
profile of T cells to ICAM-1 under NTZ was noted
(p 5 0.375; figure 3B, data in red). By contrast,
DMF induced a significant decrease in the median
number of ICAM-1–adhering T cells/FOV at T12,
dropping from 61 to 40 cells (p 5 0.039; figure 3B,
data in green). However, with DMF, there was no
decreased adhesion to VCAM-1 or MAdCAM-1.
We finally demonstrated that FTY treatment inter-
feres with the interaction between CNS- and gut-
related integrins (a4b1; a4b7) and their respective
ligands (VCAM-1 and MAdCAM-1) (figure 3). Here,
we observed a drop in CD31 T-cell adhesion to
VCAM-1 (p 5 0.027) and to MAdCAM-1 (p 5
0.0078) but not to ICAM-1 (p5 0.570), after 1 year
of FTY treatment. This functional profile strikingly
resembles what was detected in NTZ-treated MS pa-
tients. Of note, this initial decrease in binding to in-
tegrin ligands under FTY is followed by a rescue of
the profile of adhesion of T cells to VCAM-1 and
MAdCAM-1 or even, in the case of ICAM-1, an
increased adhesion profile, as observed at T36–48
(figure 3, data in black). Thus, although the circulat-
ing pool of T cells shows an increased frequency of
cells expressing a4b1 and aL, FTY seems to cause
a transient reduced ability of these T cells to bind to
the integrin ligands VCAM-1 and ICAM-1.
To investigate whether T-cell ability to adhere to
VCAM-1 in FTY-treated patient samples could be
chemically restored in vitro, binding assays in the
presence of MnCl2, which induces integrin affinity
maturation, were performed.22 Of interest, the addi-
tion of MnCl2 partially restored binding to VCAM-1
(pKW 5 0.057) even if the median number of cells/
FOV was still lower at T12 (121) as compared to T0
(183) (figure 4, 1MnCl2). These results further sug-
gest that FTY, beside a strong lymphopenic activity,
would also interfere, in an at least-partially reversible
way, with the activation profile of a4b1 integrins
expressed on the surface of T cells, further impeding
their access to the CNS.
DISCUSSION Several effective treatments are avail-
able for patients with RRMS, but some of them are
associated with severe side effects. NTZ has a strong
efficacy but is associated with a consistent risk of
developing PML (711 cases as of March 6, 2017).23
NTZ is a humanized monoclonal IgG4 antibody tar-
geting the a4 integrin subunit of a4b1, preventing
the entry of autoreactive T cells into the CNS, but
probably also of CD81 T cells fighting viral infec-
tions, thus decreasing the immune surveillance and
favoring the occurrence of PML.24,25 Intriguingly,
cases of PML have also been reported with 2 other
DMTs, namely FTY (13 cases in patients who had
not been previously on NTZ, as of July 13, 2017) and
DMF (5 cases in patients with MS and 11 in patients
with psoriasis treated with DMF-related products).
Here, we examined whether an impairment of the
immune surveillance could also be involved with
these 2 DMTs and thus be a contributing factor to
the occurrence of opportunistic infections.
First, we were able to confirm that NTZ reduces
the frequency of integrin-expressing circulating T
cells either directed to the CNS (a4b11 and aLhigh,
figure 1)11,20,21 or to the gut (a4b71, figure 2). Fur-
thermore, NTZ diminished the level of expression of
these integrins on T cells, as detected by decreased
mean fluorescence intensities (MFI) (data not
shown). Decreased detection of a4b1 or a4b7 may
be due to epitope masking by NTZ or alternatively by
NTZ-induced integrin internalization.26 This
decreased expression of integrins was associated with
a reduced adhesion of T cells to both, VCAM-1 and
MAdCAM-1, confirming that NTZ is highly effi-
cient to decrease the migration of T cells into the
CNS or into the gut.
The mode of action of phosphorylated FTY
consists in the internalization of sphingosine-1-
phosphate (S1P) receptors expressed by T cells. This
internalization prevents the egress of naive (TN) and
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central memory (TCM) cells expressing the chemokine
receptor CCR7 from lymph nodes into the blood
stream.27 This is of particular interest since peripheral
TCM cells are thought to be the efferent limb of CNS
autoimmunity.28 By contrast, effector memory (TEM)
and effector (TE) T cells, which do not express CCR7,
can exit from the lymph node, even in the presence of
FTY. Thus, the immune surveillance of the CNS,
performed by TEM would not be affected. In the pres-
ent study, we extend our understanding of the mech-
anisms of FTY. Indeed, we show that under this drug,
there is an increased frequency of T cells in the blood
Figure 3 The binding of integrins to their ligands is affected by NTZ, FTY, and DMF
The numbers of CD31 T cells adhering to VCAM-1, ICAM-1, and MAdCAM-1–immobilized receptors were quantified in an in vitro binding assay. Data were
obtained before treatment initiation (T0) and after 12months (T12) and 36–48months (T36–48) of treatment. Background values obtained from the control
DNER receptor were subtracted from the number of cells adhering to VCAM-1, ICAM-1, or MAdCAM-1. Each dot represents the mean value of 9 individual
counts (3 counts per triplicates). Data of FTY-treated patients with MS appear in black (n5 9), NTZ in red (n5 10), DMF in green (n5 9), patients under other
DMTs in blue (n5 6), and HCs in gray (n5 9). The statistical method is the same as in figures 1 and 2 (see legend to figure 1). *p, 0.05; **p, 0.01. DMF 5
dimethyl fumarate; DMT 5 disease-modifying treatment; DNER 5 Delta/Notch-like EGF-related receptor; FOV 5 field of view; FTY 5 fingolimod; HC 5
healthy control; ICAM-1 5 intercellular adhesion molecule-1; MAdCAM-1 5 mucosal vascular addressin cell adhesion molecule-1; NTZ 5 natalizumab;
Others 5 other DMTs; VCAM-1 5 vascular cell adhesion molecule-1.
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expressing integrins involved in T-cell homing to the
CNS (a4b11 and aLhigh of LFA-1; figure 1), but
a decreased frequency of those involved in T-cell hom-
ing to the gut (a4b71; figure 2). This modification in
terms of frequency is associated with a slight increase in
the MFI of the a4 and aL subunits, but not of the b1
nor b7 expression (data not shown). The increased
frequency of CNS integrin–expressing T cells in pa-
tients on FTY is explained by the higher proportion of
CCR7-negative circulating T cells (TEM and TE),
which, precisely, express more a4b1 and aL of LFA-
1, but less a4b7 than CCR71 T cells, i.e., TN and
TCM (data not shown). More surprising, we report that
these a4b11-expressing T cells exhibit a transitory,
but important, decrease in their binding to VCAM-1
at T12 (figure 3), suggesting that FTY impairs affinity
maturation and thus function of a4b1 integrin. Of
interest, the addition of manganese partially restores
integrin affinity maturation as demonstrated by the
partial induction of T-cell binding to the a4b1 integ-
rin ligand VCAM-1 (figure 4), suggesting that FTY, at
least ex vivo, indeed may induce a suboptimal function
of integrins. Such as for a4b1, there is an increased
binding of aL-expressing T cells to ICAM-1 after 3
years of treatment. Finally, similar to the a4b1
integrin/VCAM-1 couple, the binding of a4b7 to
MadCAM-1 is transitorily, but markedly, reduced
after 1 year of treatment. Although this remains
hypothetical, it is possible that the decreased a4b1
integrin–mediated binding of circulating CD31 T
cells to VCAM-1 may play a contributing role in the
CNS opportunistic infections that are observed under
FTY treatment.
The picture is different in the case of DMF. We
demonstrate that this DMT has a strong effect on
the expression and function of aL, the integrin subunit
of LFA-1, but not of a4b1 or a4b7. Indeed, DMF
induces a 46% reduction in the frequency of circulat-
ing aL-expressing T cells, and, by doing so, decreases
by 36% the number of T cells adhering to ICAM-1.
These results may bring some light on the mode of
action of DMF. The classic view poses that DMF
promotes the antioxidative stress cell machinery work-
ing as a transcriptional promoter downstream to the
activation of the transcription nuclear factor erythroid-
2-related factor 2 (Nrf2).29 But DMF has also been
shown to redirect cytokine production toward a Th2
and M2 profile on lymphocytes and microglial cells,
respectively.30,31 Furthermore and of interest, based on
in vitro models, others have suggested that DMF could
inhibit cytokine-induced E-selectin, VCAM-1, and
ICAM-1 expressions in human endothelial cells.
DMF would thus potentially disturb T-cell migration
to the CNS.32,33 Our data showing a strong inhibitory
effect of DMF on LFA-1–mediated binding of circu-
lating T cells to ICAM-1 support this hypothesis,
Figure 4 VCAM-1–binding profile of T cells isolated from FTY-treated patients is partially restored on man-
ganese treatment
The number of cells adhering to VCAM-1 was assessed in vitro amongmagnetic-activated cell sorting–isolated CD31 T cells
treated or not with MnCl2. Background values obtained from the control DNER receptor were subtracted from the number
of cells adhering to VCAM-1. Each dot represents the mean value of 9 individual counts (3 counts per triplicates). Data of
FTY-treated patients with MS appear in black (n 5 9) and HC in gray (n 5 5). The effect of the treatment duration for the
FTY-treated group was assessed using Kruskal-Wallis tests (p 5 0.019 in the absence of MnCl2 and p 5 0.054 in the
presence of MnCl2). The effect of the FTY treatment was finally tested using pairwise nonparametric Wilcoxon tests. As-
terisks represent statistically significant differences for the effect of time for a given treatment: in black if the Kruskal-
Wallis test was statistically significant; in gray if not. *p, 0.05; **p, 0.01. DNER5Delta/Notch-like EGF-related receptor;
FOV 5 field of view; FTY 5 fingolimod; HC 5 healthy control; VCAM-1 5 vascular cell adhesion molecule-1.
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suggesting that preventing activated T cells to cross the
blood brain barrier may be a significant mode of action
of DMF. A blood lymphocyte count below 500/mm3
has been observed in DMF-induced PML cases.34,35
CD81 T cells are disproportionally reduced as com-
pared to CD41 T cells,36 a factor that may favor the-
onset of PML.37,38 Of note, DMF-related PML cases
also occurred in patients with a blood lymphocyte
count above 500/mm3.39,40 Our data suggest that
DMF, by decreasing the LFA-1 binding of circulating
T cells to ICAM-1, may impede the immune surveil-
lance of the CNS, which may contribute to explain the
occurrence of PML in DMF-treated patients, in par-
ticular those who do not present with lymphopenia.
Contrasting with the 3 other DMTs, we do not
observe significant changes in the expression or the
function of integrins on the circulating T-cell pool
in the group of other DMTs. And precisely, IFN-b,
GA, or teriflunomide has not been associated with
CNS opportunistic infections, in particular PML.
Nevertheless, we acknowledge the fact that the cate-
gory of other DMTs encompasses fewer patients than
the 3 other groups of DMTs. Furthermore, the other
DMTs category is composed of 3 different com-
pounds, IFN-b being by far the most represented.
Yet, supporting the validity of our data, there is not
even a trend for a decreased frequency of integrin-
expressing circulating T cells or a diminished adhe-
sion of T cells to endothelial ligands in the other
DMTs group. It can also be noted that the values
are quite close to the median (figures 1 and 2), sug-
gesting that this group is relatively homogenous.
Thus, we conclude that the data of the other DMTs
group can be taken into consideration, despite the
relatively small sample size.
To conclude, we report for the first time, that not
only NTZ but also FTY and DMF may, by different
mechanisms, impair the T-cell–mediated immune
surveillance of the brain. These results, if confirmed by
others, may open new axes of research to explain the
few cases of PML associated with these drugs.
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